TPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy

References

• Hunger SP, Loh ML, Withlock JA, et al. Children’s oncology group’s 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957–963. doi:10.1002/pbc.24420
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures. American cancer society; 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed January 8, 2021.
   Google Scholar
• Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and Non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(17):2094–2101. doi:10.1200/JCO.2011.38.9924
   PubMed Web of Science ®Google Scholar
• Windiastuti E Childhood acute leukemia. Cipto Mangunkusumo Hospital experiences. Dipresentasikan pada Pertemuan Perhimpunan Hematologi dan Transfusi Darah Indonesia. Medan. 2011.
   Google Scholar
• Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children’s oncology group study. JAMA Oncol. 2015;1(3):287–295. doi:10.1001/jamaoncol.2015.0245
   PubMed Web of Science ®Google Scholar
• Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010;79:1211–1220. doi:10.1016/j.bcp.2010.01.006
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013;89(3):1–5.
   Web of Science ®Google Scholar
• Kapoor G, Sinha R, Naithani R, et al. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk Res. 2010;34(8):1023–1026. doi:10.1016/j.leukres.2010.01.029
   PubMed Web of Science ®Google Scholar
• Linga VG, Patchva DB, Mallavarapu KM. Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol. 2014;35(4):276–280. doi:10.4103/0971-5851.144989
   PubMedGoogle Scholar
• Ikatan Dokter Anak Indonesia. Indonesian protocol of acute lymphoblastic leukemia; 2013. Available from: https://kupdf.com/download/panduan-protokol-indonesia-all-2013_58e9fef1dc0d600d38da981c_pdf. Accessed January 8, 2021.
   Google Scholar
• Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genome Inform. 2012;10(2):117–122.
   Google Scholar
• Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS; 2003 Available from: http://ctep.cancer.gov. Accessed August 9, 2006.
   Google Scholar
• Dervieux T, Meyer G, Barham R, et al. Liquid Chromatography–tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51(11):2074–2084. doi:10.1373/clinchem.2005.050831
   Web of Science ®Google Scholar
• Rosdiana DS, Setiabudy R, Louisa M, et al. Development and method validation of 6-thioguanine and 6-methylmercaptopurine in erythrocytes using LC-MS/MS. J Pharm Sci Res. 2018;November(S):56–63.
   Google Scholar
• Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64:753–767. doi:10.1007/s00228-008-0478-6
   PubMed Web of Science ®Google Scholar
• Levinsen M, Rosthøj S, Nygaard U, et al. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol. 2015;75(1):59–66. doi:10.1007/s00280-014-2613-7
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171:109–115. doi:10.1111/bjh.13518
   PubMed Web of Science ®Google Scholar
• Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24:1258–1264. doi:10.1111/j.1440-1746.2009.05917.x
   PubMed Web of Science ®Google Scholar
• Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6mercaptopurine treatment. J Gastroenterol. 2009;44:197–203. doi:10.1007/s00535-008-2307-1
   PubMed Web of Science ®Google Scholar
• Zhu Q, Cao Q. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine. Chin Med J (Engl). 2012;125:3665–3670.
   PubMed Web of Science ®Google Scholar
• Cao Q, Zhu Q, Shang Y, et al. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion. 2009;79:58–63. doi:10.1159/000205268
   Web of Science ®Google Scholar
• Lee JH, Kim TJ, Kim ER, et al. Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Chron’s disease. PLoS One. 2017;12(12):1–13. doi:10.1371/journal.pone.0188925
   Web of Science ®Google Scholar
• Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine s-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001–2008. doi:10.1093/jnci/91.23.2001
   PubMed Web of Science ®Google Scholar
• Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol. 2001;51(5):475–477. doi:10.1046/j.1365-2125.2001.01371.x
   PubMed Web of Science ®Google Scholar
• Lennard L, Cartwright CS, Wade R, et al. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2012;7(1):125–136.
   Web of Science ®Google Scholar
• Ladislava B, Michal K, Katerina W, et al. Gene polymorphisms and inflammatory bowel diseases. In: Szabo I, editor. Inflammatory Bowel Disease. Chapter 2. 2012.
   Google Scholar
• Lennard L, Cartwight S, Wade R, et al. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukemia. Br J Clin Pharmacol. 2012;76(1):125–136. doi:10.1111/bcp.12066
   Web of Science ®Google Scholar
• Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in east asia: prospects for clinical application fo NUDT15 genotyping. J Gastroenterol. 2018;53:172–180. doi:10.1007/s00535-017-1416-0
   PubMed Web of Science ®Google Scholar
• Ho CC, Fong WY, Lee YH, et al. Novel tetra-primer ARMS-PCR assays for thiopurine intolerance susceptibility mutations NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C) in East Asians. Genes. 2017;285(8):1–8.
   Google Scholar
• Chrzanowska M, Kolecki P, Cichocka BD, et al. Metabolites of mercaptopurine in red blood cell: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci. 1999;8:329–334. doi:10.1016/S0928-0987(99)00027-5
   PubMed Web of Science ®Google Scholar
• Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1990;8(3):567–574.
   Google Scholar
• Sheffield LJ, Irving P, Gupta A, et al. Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics. 2009;10(7):1091–1099. doi:10.2217/pgs.09.60
   Web of Science ®Google Scholar
• Kuzelicki NK, Rascan IM. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics. 2009;10(8):1309–1322.
   Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report of mercaptopurine. 2011.
   Google Scholar
• Dervieux T, Hancock M, Evans W, et al. Effect of methotrexate on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia. 2002;16:209–212. doi:10.1038/sj.leu.2402373
   Web of Science ®Google Scholar
• Goel RM, Blaker P, Mentzer A, et al. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6(3):138–146. doi:10.1177/2040622315579063
   PubMed Web of Science ®Google Scholar
• Broekman MMTJ, Coenen MJH, Wanten GJ, et al. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Aliment Pharmacol Ther. 2017;46:953–963. doi:10.1111/apt.14323
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Carrillo MW, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;1–11.
   Web of Science ®Google Scholar